Sanofi
SAN.PAEuronextTrackedESG Rated: 2/2 ProvidersHealth CareDiversifiedMSCI: A (Average)Sustainalytics: 18.8 · Low
Public exchange feeds are not currently returning active trading data for Sanofi (SAN.PA). This company may be delisted, bankrupt, acquired, or halted. To preserve data integrity, prices are never displayed as $0.00. Sourced ESG ratings and sustainability disclosures remain cataloged below.
- Coverage
- Rated universe Carries an MSCI or Sustainalytics observation.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Market data unavailableObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Market data unavailable
Massive Stock Widgets has not returned a current, verifiable snapshot for Sanofi (euronext:SAN.PA). Check again later.
Company Profile & Business Model Overview
Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. It develops and markets prescription medicines and vaccines, with a portfolio spanning immunology, oncology, rare diseases and vaccines.
Sustainability Strengths & Catalysts (Pros)
- Dupixent Blockbuster Success: Sanofi's Dupixent achieved €13 billion sales in 2024 with patent protection beyond 2031, targeting €22 billion by 2030, providing exceptional revenue visibility and growth runway.
- Consistent Dividend Growth: The company offers 30 consecutive years of dividend increases with proposed €3.92 per share for 2024, demonstrating reliable shareholder returns and financial stability.
- Strong Pipeline and Innovation: With 86 clinical-stage projects and 31 in Phase 3, launches contributed 11% of sales with new blockbuster Beyfortus, showcasing successful R&D execution and portfolio diversification.
Material Risks & Governance Concerns (Cons)
- Pipeline Execution Risk: The recent itepekimab Phase 3 failure caused 6% stock decline, highlighting significant risks in replacing Dupixent revenues as competition approaches post-2031.
- Pricing Pressure and Competition: Dupixent faces U.S. pricing pressures and emerging IL-13/JAK inhibitor competition, while Aubagio (€2 billion sales) loses patent protection imminently.
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
MSCI ESG industry rating benchmark.
Low
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Sanofi (SAN.PA)'s ESG rating and sustainability score?
Sanofi (SAN.PA) currently holds an MSCI ESG rating of A (Average) and a Sustainalytics ESG Risk Score of 18.8 (Audited Risk Band). Ratings evaluate environmental emissions, labor standards, board independence, and regulatory compliance.
Is Sanofi considered an ESG leader or laggard in Health Care?
Independent benchmark status for Sanofi is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for Sanofi?
Key material risks for Sanofi include: Pipeline Execution Risk: The recent itepekimab Phase 3 failure caused 6% stock decline, highlighting significant risks in replacing Dupixent revenues as competition approaches post-2031.; Pricing Pressure and Competition: Dupixent faces U.S. pricing pressures and emerging IL-13/JAK inhibitor competition, while Aubagio (€2 billion sales) loses patent protection imminently.. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.